Secondary breast cancer: Why does cancer recur?
HTRA1 and HTRA2 expression differentially modulate the clinical prognosis of cancer: a multi-omics analysis using bioinformatics approaches
PDF) Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?
Catalog of genetic progression of human cancers: breast cancer
Current Oncology, Free Full-Text
PDF] Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Comparative analysis of protein-protein interaction networks in metastatic breast cancer
Medical Sciences, Free Full-Text
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer. - Abstract - Europe PMC
US20040137538A1 - Cancer comprehensive assay kit for identifying cancer protein patterns - Google Patents
Characterization of the genomic landscape and actionable mutations
ESMO Open on X: In this ctDNA analysis of the #FUTURE trial
